Search Results
Dec 09, 2025, 01:00 ET Håvors CM öppnar kontor i Köpenhamn för att erbjuda närmare och mer respons stöd till nordiska och europeiska universitet
för institutioner att fatta datadrivna beslut och uppnå sina registreringsmål. Med kontor i Kanada, Storbritannien och nu Danmark fortsätter Azorus att öka sin närvaro i hela Europa och stötta högre utbildningsinstitutioner med teknik som är utformad för deras unika behov.Logotyp -
More news about: AZORUS CRM
Dec 08, 2025, 18:30 ET Club Med Expands Brand Presence in Canada with the Announcement of Club Med Tremblant
of Club Med Québec Charlevoix.MONT-TREMBLANT, QC, Dec. 8, 2025 /PRNewswire/ -- Club Med, the world leader in premium all-inclusive mountain and beach resorts, today announced the development of Club Med Tremblant,
More news about: Club Med
Dec 08, 2025, 16:13 ET Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
Carroll D, Popa A, Hejal R, et al. 1601: Evaluation of timing of first dose antibiotic administration in patients with sepsis or septic shock. Crit Care Med. 2019;47(1):776
More news about: Hikma Pharmaceuticals USA Inc.
Dec 08, 2025, 12:00 ET Castlight Health Partners With Noom to Expand Access to Personalized Programs for Weight and Chronic Conditions
seamlessly discover, access, and enroll in Noom programs – including Noom Weight, Noom Med, Noom Diabetes, and Noom Diabetes Prevention – directly through the Castlight app. Members also gain access to GLP-1s through Noom Med, helping those prescribed these medications integrate them effectively with lifestyle
More news about: Castlight Health
Dec 08, 2025, 12:00 ET Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction. J Med Chem. 2018;61(11):4832-4850. doi:10.1021/acs.jmedchem.8b00071Hernández-Boluda JC, Czerw T. Transplantation algorithm for myelofibrosis in
More news about: Sumitomo Pharma America
Dec 08, 2025, 11:07 ET Cardiovascular Diagnostic Device Market to Reach $21.1 billion, Globally, by 2034 at 7.2% CAGR: Allied Market Research
decision-making. Moreover, increasing investments in healthcare infrastructure, particularly in emerging economies, and strategic collaborations between med-tech companies and digital health startups are expected to propel the cardiovascular diagnostic device market growth.Report Overview:The
More news about: Allied Market Research
Dec 08, 2025, 09:00 ET Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data
Digital health application integrating wearable data and behavioral patterns improves metabolic health. NPJ Digit Med. 2023 Nov 25;6(1):216. doi: 10.1038/s41746-023-00956-y. Erratum in: NPJ Digit Med. 2024 Jan 12;7(1):9.
More news about: Abbott
Dec 08, 2025, 04:40 ET 歌禮口服小分子GLP-1藥物ASC30在肥胖或超重受試者中進行的美國13周II期研究顯示經安慰劑校正後的體重下降高達7.7%，且胃腸道耐受性更佳
Metab. 2023;25:2642–26492. N Engl J Med. 2025;393:1796-1806 電話溝通會議/網絡直播普通話場時間：中國標準時間2025年12月8日（今日）晚上8:00入會鏈接：
More news about: 歌禮製藥有限公司
Dec 08, 2025, 04:40 ET Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
Metab. 2023;25:2642–26492. N Engl J Med. 2025;393:1796-1806Conference Calls / WebcastsMandarin SessionTime: 8:00 p.m.
More news about: Ascletis Pharma Inc.
Dec 06, 2025, 15:40 ET Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC
https://www.bizengrihcp.com/piSchram AM, Goto K, Kim DW, et al. Efficacy of zenocutuzumab in NRG1 fusion–positive cancer. N Engl J Med. 2025;392:566-76.
More news about: Partner Therapeutics, Inc.
Dec 05, 2025, 17:45 ET AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
NCT05039099).1Maier M et al., Sci Transl Med. 2018;10(470).2Marlow TR et al., Neurobiol Dis. 2025;216:107124.About AP-101AP-101 is an investigational human-derived
More news about: AL-S Pharma AG
Dec 05, 2025, 09:00 ET Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
9 Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-319.10 French
More news about: Jazz Pharmaceuticals plc
Dec 05, 2025, 08:00 ET Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 2025 ASH Annual Meeting
LinkedIn.Footnotes1 Gotlib J, Kluin-Nelemans, HC, George TI, et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016;374:2530–2541.2 Sperr WR, Kundi M, Alvarez-Twose I, et al. International Prognostic Scoring System for Mastocytosis (IPSM):
More news about: Blueprint Medicines, a Sanofi company
Dec 04, 2025, 11:00 ET Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
vCampbell WW, et al. J Gerontol A Biol Sci Med Sci. 2023;78(1):67–72.vi
More news about: Abbott
Dec 04, 2025, 08:10 ET ProPharma Welcomes Dan Ryan as President of Clinical Research Solutions
ProPharmaFor the last 25 years, ProPharma has improved the health and wellness of patients by providing advice and expertise that empowers biotech, med device, and pharmaceutical organizations of all sizes to confidently advance scientific breakthroughs and introduce new therapies. With deep domain expertise
More news about: ProPharma Group Holdings LLC
Dec 04, 2025, 07:00 ET Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate's Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America
Miyake-Stoner SJ, et al. Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open label clinical trial. Commun Med (Lond). 2025b;5(1):392. Published 2025 Sep 24. doi:10.1038/s43856-025-01147-4.
More news about: Replicate Bioscience
Dec 04, 2025, 06:00 ET EUROPE'S 50 BEST BARS, DEBUTERAR MED FOKUS PÅ BARER ÖVER HELA KONTINENTEN
America's 50 Best Bars och Asia's 50 Best Bars kommer denna regionala lista att hylla kontinentens finaste dryckesdestinationer och förse konsumenterna med den mest betrodda, expertkuraterade guiden till exceptionella barupplevelser.Emma Sleight, innehållschef för Europe's 50 Best Bars, sade: "Vi
More news about: 50 Best
Dec 04, 2025, 03:00 ET iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new non-clinical data at ASH
HEMA-MED clinical trial.Professor Alessandro Vannucchi, Professor of Hematology and Department Head of the Center for Research and Innovation in Myeloproliferative Neoplasms (CRIMM) at the University of Florence, Florence, Italy and Principal Investigator of the HEMA-MED study
More news about: iOnctura
Dec 03, 2025, 16:20 ET Marquis Who's Who Recognizes Spotlight Biographees for the Fourth Quarter of 2025
Philip, MDSenior Consultant Anesthesiologist, Director of Anesthesia Bioengineering, Brigham & Women's HospitalPresident, Med Man SimulationsKyriacos Chris Skevas, CPAOwner, FounderKyriacos Chris Skevas, CPA PLLCJewel Montgomery Smay,
More news about: Marquis Who's Who
Dec 03, 2025, 09:43 ET VIO Med Spa Brings Premium Aesthetic and Wellness Services to East Northport, Opening December 9
owns the successful VIO Med Spa in Patchogue and continues to bring their shared passion for health, beauty, and entrepreneurship to Long Island through the new East Northport opening. Together, Regoukos and the Galanis brothers are slated to open more than 20 additional VIO Med Spa locations throughout
More news about: VIO Med Spa
Dec 02, 2025, 16:40 ET New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
32023927; PMCID: PMC7037706.Horie et al., CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease. Nat Med 29, 1954–1963 (2023). https://doi.org/10.1038/s41591-023-02443-z.
More news about: Eisai Inc.
Dec 02, 2025, 04:34 ET 復星旅文2026戰略發佈：聚焦三大核心產品線，18個合作項目集中籤約
超級度假村直擊國內業態單一、觀光為主的景區痛點，以擁有75年歷史的全球度假領導品牌Club Med地中海俱樂部為核心，通過高品質的服務、多元的文化氛圍以及豐富的體驗內容，為傳統景區提供一站式度假轉型解決方案。會上，Club Med Joyview地中海‧鄰境與Club Med Urban Oasis地中海‧白日方舟正式發佈2.0品牌戰略。地中海‧鄰境將全新定位為「鄰近城市，鏈接景區的歡聚度假營地」，強化與周邊景區資源聯動，打造豐富且深度的在地體驗。地中海‧白日方舟則致力於打造「觸手可及的一站式城市度假地」，強調「城市度假，此時此地」的體驗理念。
More news about: 復星旅遊文化集團
Dec 01, 2025, 19:35 ET Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Alzheimers Dis 2025; 1 (12), 13.Horie, K. et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease. Nat Med. 31, 2044–2053 (2025).
More news about: Eisai Inc.
Dec 01, 2025, 08:00 ET MediView Achieves First CE Mark, Bringing Augmented Reality to European Healthcare
and marking a global inflection point for immersive technologies in healthcare.About MediView MediView is a Cleveland, OH based med-tech company working to advance healthcare delivery through intuitive visualization, seamless collaboration, and data-driven insights. MediView's comprehensive
More news about: MediView XR, Inc.
Dec 01, 2025, 08:00 ET MediView Achieves First CE Mark, Bringing Augmented Reality to European Healthcare
and marking a global inflection point for immersive technologies in healthcare.About MediView MediView is a Cleveland, OH based med-tech company working to advance healthcare delivery through intuitive visualization, seamless collaboration, and data-driven insights. MediView's comprehensive
More news about: MediView XR, Inc.